Talphera

TLPH

Börsenwert 56,1 Mio. $

Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m.

SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript